Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wolf, P; Hofer, A; Legat, FJ; Bretterklieber, A; Weger, W; Salmhofer, W; Kerl, H.
Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
Br J Dermatol. 2009; 160(1):186-189
Doi: 10.1111/j.1365-2133.2008.08926.x
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Wolf Peter
- Co-Autor*innen der Med Uni Graz
- Bretterklieber Agnes
- Hofer Angelika
- Kerl Helmut
- Legat Franz
- Salmhofer Wolfgang
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Some patients with plaque-type psoriasis respond slowly to treatment with etanercept. In such cases combining etanercept with conventional treatments might be helpful. To investigate whether treatment with 311-nm ultraviolet (UV) B can improve the therapeutic response in patients treated with etanercept. Four women and one man (mean age 57 years, range 48-66) with moderate to severe plaque-type psoriasis who had received standard treatment with etanercept 50 mg twice weekly for 6 weeks without Psoriasis Area and Severity Index (PASI) reduction of 75% or greater (of initial mean PASI of 16.0, range 15.4-20.4) were enrolled in the study. Starting at 6 weeks, 311-nm UVB treatment was given to a randomly selected body half (left or right, excluding the head) for another 6 weeks, while all patients continued receiving etanercept. The patients were monitored by half-body PASI at weekly intervals. During the 6-week irradiation regimen, 311-nm UVB significantly bolstered the therapeutic response in the patients on etanercept treatment. After 6 weeks of 311-nm UVB, the patients had a mean PASI on their UV-irradiated body halves of 1.6 (range 0.6-3.3) vs. 4.7 (range 1.4-8.6) on nonirradiated body halves (P = 0.0192, paired two-tailed t-test), compared with 10.7 (range 6-16.4) and 10.5 (range 5.2-16.4) at start of 311-nm UVB treatment. The overall mean PASI reduction from baseline (i.e. at etanercept start) was 89% vs. 68%, respectively (P = 0.0009 and P = 0.0088). Treatment with 311-nm UVB significantly accelerates and improves the clearance of psoriatic lesions in patients responding slowly to etanercept monotherapy.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
- Combined Modality Therapy -
- Etanercept -
- Female -
- Humans -
- Immunoglobulin G - therapeutic use
- Male -
- Middle Aged -
- Psoriasis - drug therapy
- Psoriasis - pathology
- Psoriasis - radiotherapy
- Receptors, Tumor Necrosis Factor - therapeutic use
- Treatment Outcome -
- Ultraviolet Therapy - methods
- Find related publications in this database (Keywords)
- 311 nm
- combination therapy
- etanercept
- psoriasis
- ultraviolet